Quantcast
Last updated on April 16, 2014 at 8:52 EDT

Latest Sepracor Stories

2012-08-21 02:26:21

DALLAS, Texas, August 21, 2012 /PRNewswire/ -- RnRMarketResearch.com adds a new market research report "Global Markets for Asthma & COPD Drugs" to its store. This report projects a five-year CAGR of 4.4% for the Global Asthma and Chronic Obstructive Pulmonary Disease Drugs market. The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012...

2012-07-26 23:00:05

Enthusiasm among sexual dysfunction specialists for this breakthrough product in the treatment of male premature ejaculation is generating increasing demand from urologists, gynecologists and general practitioners. Huntington Beach, CA (PRWEB) July 26, 2012 Absorption Pharmaceuticals, LLC today announced the hiring of four key sales executives to meet the growing demand for Promescent® - the most effective medical solution for treating male premature ejaculation (PE). Jay Lovin, hired...

2012-07-12 02:27:33

BRIDGEWATER, N.J., July 12, 2012 /PRNewswire/ -- Sanofi US announced today that its product MACI®( )(matrix-induced autologous chondrocyte implant) met its co-primary endpoint in a two-year, randomized, controlled clinical trial compared to microfracture, a surgical procedure designed to stimulate the growth of new cartilage. MACI uses a patient's own (autologous) cultured cartilage cells (chondrocytes) to repair articular cartilage defects in the knee joint. The results from this pivotal...

2012-05-29 02:26:51

PITTSBURGH, May 29, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Mylan Specialty L.P., f/k/a Dey Pharma, L.P., has entered into a settlement agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., that will resolve the parties' patent litigation in connection with Mylan Specialty's Abbreviated New Drug Application (ANDA) for Levalbuterol Hydrochloride (HCl) Inhalation Solution, 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL. Levalbuterol HCl is the...

2012-05-24 14:22:15

PITTSBURGH, May 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Mylan Specialty L.P., f/k/a Dey Pharma, L.P., has entered into an agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., to resolve the parties' patent litigation relating to Sunovion's Brovana® product. The U.S. District Court for the Southern District of New York's Final Judgment and Order notes that the parties have entered into a settlement and license agreement and that Sunovion has...

2012-04-23 03:13:35

Tokyo, Apr 17, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the insomnia treatment Lunesta(R) (eszopiclone) in Japan on April 18.Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc.; currently a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd.), is the first non-benzodiazepine type GABAA agonist to be launched in Japan in 12 years, and is believed to enhance GABA activity while exerting hypnotic...

2012-04-18 06:25:02

NEW YORK, April 18, 2012 /PRNewswire/ -- In an act reminiscent of David defeating Goliath, StrikeForce Communications--the independent healthcare agency that has been flouting tradition ever since it burst upon the scene in late 2009--has won the Gold Award for Best Product Launch at the National Advertising Awards held in Washington, DC last week. The agency, which was nominated in five of the ten award categories, also took the Silver Award for Best Branded Print Campaign. Both...

2012-03-16 08:50:41

PARIS, March 16, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Pluromed Inc. announced today that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts. The acquisition is subject to customary closing conditions. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Pluromed has developed a proprietary polymer technology, called Rapid Transition...

2012-02-10 16:17:00

PITTSBURGH, Feb. 10, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that a jury has rendered an unfavorable verdict in a patent infringement lawsuit filed by Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., against Mylan Inc., Mylan Pharmaceuticals Inc., Dey Inc. and Dey Pharma, L.P. in relation to Dey's Abbreviated New Drug Application (ANDA) for Levalbuterol Hydrochloride (HCl) Inhalation Solution, 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL...

2012-02-06 08:15:00

MALVERN, Pa., Feb. 6, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced the appointment of two executive officers, effective immediately. Andrew I. Koven has been named Executive Vice President, Chief Administrative Officer and General Counsel, and Mark A. Glickman has been named Senior Vice President, Sales. "The leadership appointments we are announcing today advance our efforts to help position Auxilium for...